In what represents its first patenting, Austin, Texas-based Slipstream Solutions LLC is seeking protection for systems and methods for treating fluid stasis (e.g., edema) that employ an airstream to move static fluid to natural drainage areas such as lymph nodes or ducts.
Deciphera Pharmaceuticals LLC has described serine/threonine-protein kinase ULK1 and/or ULK2 and/or leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer.
Genescience Pharmaceuticals Co. Ltd. has divulged MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of rheumatoid arthritis and radiographic axial spondyloarthritis (ankylosing spondylitis).
Scientists from Abbvie Deutschland GmbH & Co. KG and Abbvie Inc. have identified radiolabeled compounds capable of imaging and targeting microtubule-associated protein Tau (PHF-tau; MAPT) aggregates acting as positron emission tomography (PET) imaging agents reported to be useful for the diagnosis of progressive supranuclear palsy.
Acurex Biosciences Corp. has synthesized phenothiazines acting as ferroptosis inhibitors reported to be useful for the treatment of mitochondrial disease.
Japan Tobacco Inc. has disclosed pyrazolopyrimidine compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, inflammatory bowel disease and more.
In what represents its first patenting, Sonura LLC has been issued with a patent for an aural device designed to protect the hearing of infants in a neonatal intensive care unit (NICU) by active filtering, while, at the same time, providing aural stimulation for neurological development.
Auron Therapeutics Inc. has described proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a histone acetyltransferase KAT2A and/or KAT2B (PCAF)-targeting moiety through a linker.
Artivila Biopharma has divulged azepine fused ring compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of coronary heart disease, inflammatory bowel disease, liver diseases, myocardial infarction, neurodegeneration, stroke, inflammatory disorders and renal disorders, among others.
Shanghai Huilun Pharmaceutical Co. Ltd. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, multiple sclerosis, Charcot-Marie-Tooth disease, urinary incontinence, cough and arrhythmia.
RSS
